Aptevo Therapeutics Inc. APVO
Biotechnology: Pharmaceutical Preparations · data as of November 13, 2026
Aptevo Therapeutics Inc. (APVO) is a healthcare company listed in the US with a market value of about $3M.
Its overall Stock Analiz score is 0.8 out of 5 (weak). The strongest part is value (2/5); the weakest is future growth (0/5).
Key numbers: a P/E of 0.0, a 5-year average ROIC of -120%.
About Aptevo Therapeutics
Aptevo Therapeutics is listed in the US and classified in biotechnology: pharmaceutical preparations. Revenue went from $10M in 2016 to $12M in 2021, growth of about 4.2% a year. It was profitable in 2 of the last 10 years in our data. Its share count rose by 3624178% over three years (dilution for shareholders).
Score: 0.8 / 5
Checks passed
- P/E below 25
- P/E below the industry median
- More cash than debt, or low debt to equity
- Liabilities below 60% of assets
Checks not passed
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Profit margin improving
- 3-year free cash flow growth above 10% a year
- Strong R&D investment or growth above 20%
Valuation
Growth and quality
Financials, last 10 years
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | $12M | $4M | $32M | $23M | $15M | $10M |
| Net income | -$26M | -$24M | -$17M | $8M | -$28M | -$18M | -$40M | -$54M | $7M | -$112M |
| Free cash flow | — | — | — | -$21M | -$22M | -$29M | -$43M | -$52M | -$43M | -$39M |
| EPS (diluted) | $-5.82 | $-2097.35 | $-55607.34 | $61348.03 | $-237186.31 | $-204363.17 | $-541581.93 | $-1307455.40 | $180527.31 | $-3036141.19 |
| Net margin | — | — | — | — | -231.5% | -411.9% | -124.8% | -232.8% | 47.6% | -1125.8% |
| ROIC | -119.5% | -191.4% | -124.7% | -79.6% | -86.4% | -46.0% | -90.0% | -82.2% | -31.1% | -172.9% |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
What analysts expect
The average 12-month price target from 2 analysts is $25.50, 4192% above the current price; targets range from $21.00 to $30.00; the consensus rating is “none”; expected EPS is $-16.02 for the fiscal year ending December 31, 2026.
Frequently asked questions
What is Aptevo Therapeutics’s P/E ratio?
About 0.0, based on the last twelve months of diluted earnings per share.
Does Aptevo Therapeutics pay a dividend?
Not currently.
Is Aptevo Therapeutics a good stock to buy?
We do not give buy or sell advice. Aptevo Therapeutics scores 0.8 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.